Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2005

01-08-2005 | Original Article

Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction

Authors: Riemer H. J. A. Slart, Jeroen J. Bax, Jaep de Boer, Antoon T. M. Willemsen, Piet H. Mook, Matthijs Oudkerk, Ernst E. van der Wall, Dirk J. van Veldhuisen, Pieter L. Jager

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2005

Login to get access

Abstract

Purpose

Dual-isotope simultaneous acquisition (DISA) single-photon emission computed tomography (SPECT) is an attractive technique as it permits assessment of both myocardial glucose metabolism and perfusion within a single session, but few data on its accuracy for the assessment of viability are available as yet. In the present study, DISA SPECT was compared with positron emission tomography (PET) for the detection of myocardial viability in normal and dysfunctional left ventricular (LV) myocardium.

Methods

Fifty-eight patients with chronic coronary artery disease and LV dysfunction (LV ejection fraction 33±12%) were studied. Patients underwent a 1-day dipyridamole stress 99mTc-sestamibi/18F-fluorodeoxyglucose (18FDG) DISA SPECT and 13N-ammonia/18FDG PET protocol. Within 1 week, resting MRI was performed to assess contractile function. Comparison of PET and SPECT data was performed using both visual and quantitative analysis.

Results

The correlation of normalised activities of the flow tracers 99mTc-sestamibi and 13N-ammonia was good (r=0.82; p<0.001). The correlation between the two 18FDG studies was also good (r=0.83; p< 0.001). The agreement for the assessment of viability for all segments between DISA SPECT and PET was 82%, with a κ-statistic of 0.59 (95% CI 0.53–0.64), without a significant difference; in dysfunctional segments only, the agreement was 82%, with a κ-statistic of 0.63 (95% CI 0.56–0.70), without a significant difference. When the DISA SPECT data were analysed visually, the agreement between DISA SPECT and PET was 83%, with a κ-statistic of 0.58 (95% CI 0.52–0.63), without a significant difference. Moreover, there was no significant difference between visual and quantitative DISA SPECT analysis for the detection of viability.

Conclusion

This study shows an overall good agreement between 99mTc-sestamibi/18FDG DISA SPECT and PET for the assessment of myocardial viability in patients with severe LV dysfunction. Quantitative or visual analysis of the SPECT data did not influence the agreement with PET, suggesting that visual assessment may be sufficient for clinical purposes.
Literature
1.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151–8.CrossRefPubMed
2.
Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60–9.
3.
Bax JJ, Cornel JH, Visser FC, Fioretti PM, Van Lingen A, Reijs AE, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996;28:558–64.CrossRefPubMed
4.
Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8.PubMed
5.
Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995;91:1697–705.PubMed
6.
Delbeke D, Videlefsky S, Patton JA, Campbell MG, Martin WH, Ohana I, et al. Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med 1995;36:2110–9.PubMed
7.
Fukuchi K, Katafuchi T, Fukushima K, Shimotsu Y, Toba M, Hayashida K, et al. Estimation of myocardial perfusion and viability using simultaneous 99mTc-tetrofosmin-FDG collimated SPECT. J Nucl Med 2000;41:1318–23.
8.
Sandler MP, Videlefsky S, Delbeke D, Patton JA, Meyerowitz C, Martin WH, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870–8.CrossRefPubMed
9.
Matsunari I, Kanayama S, Yoneyama T, Matsudaira M, Nakajima K, Taki J, et al. Myocardial distribution of 18F-FDG and 99mTc-sestamibi on dual-isotope simultaneous acquisition SPET compared with PET. Eur J Nucl Med Mol Imaging 2002;29:1357–64.CrossRefPubMed
10.
Bax JJ, Visser FC, Poldermans D, Van Lingen A, Elhendy A, Boersma E, et al. Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients. J Nucl Cardiol 2002;9:587–93.
11.
Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, Maki M, Ruotsalainen U, Harkonen R, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994;35:989–98.
12.
Schinkel AF, Bax JJ, Valkema R, Elhendy A, van Domburg RT, Vourvouri EC, et al. Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med 2003;44:877–83.
13.
Schelbert HR, Beanlands R, Bengel F, Knuuti J, Dicarli M, Machac J, et al. PET myocardial perfusion and glucose metabolism imaging: part 2—guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557–71.
14.
De Boer J, Slart RH, Blanksma PK, Willemsen AT, Jager PL, Paans AM, et al. Comparison of 99mTc-sestamibi–18F-fluorodeoxyglucose dual isotope simultaneous acquisition and rest-stress 99mTc-sestamibi single photon emission computed tomography for the assessment of myocardial viability. Nucl Med Commun 2003;24:251–7.
15.
Kool W, Willemsen ATM, Paans AMJ, Piers DA. Convolution based triple energy window crosstalk correction for DISA SPECT [abstract]. J Nucl Med 1997;38.
16.
Hendel RC, Corbett JR, Cullom SJ, DePuey EG, Garcia EV, Bateman TM. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002;9:135–43.
17.
Ficaro EP, Kritzman JN ,Corbett JR . Development and clinical validation of normal Tc-99m sestamibi database: comparison of 3D-MSPECT to Cequal [abstract]. J Nucl Med 1999;40 (suppl).
18.
van der Geest RJ, Buller VG, Jansen E, Lamb HJ, Baur LH, van der Wall EE, et al. Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. J Comput Assist Tomogr 1997;21:756–65.
19.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.PubMed
20.
Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York; 1981.
21.
Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller-Davis C, Dilsizian V. [18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998;97:843–50.
22.
Camici PG, Wijns W, Borgers M, De Silva R, Ferrari R, Knuuti J, et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997;96:3205–14.PubMed
23.
24.
Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451–60.CrossRefPubMed
25.
Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527–33.CrossRefPubMed
26.
Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997;30:1693–700.CrossRefPubMed
27.
Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994;90:2687–94.
28.
Canty J-MJ, Fallavollita JA. Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology. Am J Physiol 1999;277:H417-22.
29.
Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513–23.PubMed
30.
Vanoverschelde JL, Melin JA. The pathophysiology of myocardial hibernation: current controversies and future directions. Prog Cardiovasc Dis 2001;43:387–98.
31.
Rambaldi R, Poldermans D, Bax JJ, Boersma E, Valkema R, Elhendy A, et al. Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. Am J Cardiol 1999;84:130–4.
32.
Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352–60.
33.
Slart RH, Que TH, van Veldhuisen DJ, Poot L, Blanksma PK, Piers DA, et al. Effect of attenuation correction on the interpretation of 99mTc-sestamibi myocardial perfusion scintigraphy: the impact of 1 year’s experience. Eur J Nucl Med Mol Imaging 2003;30:1505–9.
34.
Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176–9.
35.
Martin WH, Delbeke D, Patton JA, Hendrix B, Weinfeld Z, Ohana I, et al. FDG-SPECT: correlation with FDG-PET. J Nucl Med 1995;36:988–95.
36.
Bax JJ, Visser FC, Blanksma PK, Veening MA, Tan ES, Willemsen TM, et al. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med 1996;37:1631–6.PubMed
37.
Chen EQ, MacIntyre WJ, Go RT, Brunken RC, Saha GB, Wong CY, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997;38:582–6.
Metadata
Title
Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction
Authors
Riemer H. J. A. Slart
Jeroen J. Bax
Jaep de Boer
Antoon T. M. Willemsen
Piet H. Mook
Matthijs Oudkerk
Ernst E. van der Wall
Dirk J. van Veldhuisen
Pieter L. Jager
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-1785-0

Other articles of this Issue 8/2005

European Journal of Nuclear Medicine and Molecular Imaging 8/2005 Go to the issue

Image of the Month

Erdheim-Chester disease: 99mTc-MDP bone scan provides the diagnosis

Original Article

Impact of axillary nodal metastases on lymphatic mapping and sentinel lymph node identification rate in patients with early stage breast cancer

Original Article

Biodistribution and excretion of radioactivity after the administration of 166Ho-chitosan complex (DW-166HC) into the prostate of rat

Original Article

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics

Letter to the Editor

Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus

Original Article

Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers